ABY-029 imaging for head and neck cancer surgery
Part of Cancer clinical trials.
This trial is testing a special imaging agent called ABY-029 that is given before surgery for head and neck cancer. The goal is to see if it can help surgeons see the tumor more clearly during the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer called squamous cell carcinoma, and you are scheduled for surgery to remove it.
- Your doctor believes the tumor can be removed with surgery.
- You are 18 years or older.
- You do not have a history of moderate or severe liver or kidney problems.
- You are not pregnant or breastfeeding.
- You are not currently taking any medication that targets EGFR (a protein on cancer cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests a new imaging agent called ABY-029 during surgery for high-grade glioma (a type of brain tumor). It helps doctors see the tumor more clearly, which may improve removal.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.